Anavex Life Sciences Corp. (AVXL) income statement
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.59−0.08 (-11.39%)
Close on Nov 20, 2026Market cap $54.83MP/E –Yield –
Anavex Life Sciences Corp. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -43.1%
Financial strength
- Current ratio
- –
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- –
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.49
- Dividend yield
- –
See a number that looks wrong?